An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder.
OBJECTIVE
To collect pilot data assessing the safety, tolerability, and efficacy of tomoxetine, a nonstimulant norepinephrine enhancer, in pediatric attention deficit hyperactivity disorder (ADHD).


METHODS
An open-label trial of tomoxetine in pediatric ADHD was conducted as part of a multisite clinical trial. Following a baseline assessment, an ascending dose titration was completed during 10 weekly visits.


RESULTS
Ten subjects were enrolled at baseline, with eight completing the study. Seven of the eight remaining subjects met efficacy criteria. Significant decreases in symptom severity ratings by parents and study investigators were found. The medication was well tolerated, with transient appetite suppression the most frequently reported side effect. However, subjects' weights remained stable across study visits.


CONCLUSIONS
These preliminary findings suggest that tomoxetine may hold promise as a treatment for pediatric ADHD.
Kratochvil
C J
CJ
Department of Psychiatry, University of Nebraska Medical Center, Omaha 68191-5581, USA. ckratoch@unmc.edu
Bohac
D
D
Harrington
M
M
Baker
N
N
May
D
D
Burke
W J
WJ
D000293:Adolescent; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology; D002648:Child; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D011437:Propylamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D000928:Antidepressive Agents; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride